Dr. Izumchenko received his Bachelor of Laboratory Medicine (B.Med.Lab.) and Master degree in Clinical Biochemistry (M.Med.Sc.) from Ben-Gurion University (BGU) School of Medicine, Israel, where he graduated summa cum laude from the Faculty of Health Sciences. He received his Ph.D. from Ben-Gurion University via the BGU/Fox Chase Cancer Center Partnership Graduate Research Program. He has performed thesis work in the laboratory of Dr. Erica Golemis, an internationally recognized cancer biologist, and his studies provided some of the earliest insights on the role of NEDD9 in the early stages of cancer development. He completed his first postdoctoral training with Dr. Kevin Brown and Dr. Stratford May at the University of Florida, with an NIH postdoctoral fellowship supporting his research. His studies described a novel mechanism by which dysregulation of genomic stability drives cancer development. Dr. Izumchenko joined the lab of Dr. David Sidransky at Johns Hopkins University in 2012, where he carried out seminal work in defining the clonal evolution and heterogeneity in several solid tumor types, at both the genetic and epigenetic levels. Based on his record of research accomplishments, he was invited to join the Department of Otolaryngology as an Instructor in 2016, and subsequently was promoted to the rank of Assistant Professor in May, 2017. Dr. Izumchenko joined the Department of Medicine at the University of Chicago in 2019. His research focus is on understanding the complex interplay between the genetic and epigenetic alterations in carcinogenesis and disease progression, and on exploiting this understanding for developing novel biomarkers for diagnosis and risk stratification as well as in identifying targets for therapeutic intervention. Specifically, he is interested in defining the drivers underlying the premalignant progression and early immune evasion. Dr. Izumchenko has focused his research on cancers of upper aerodigestive tract, which is a very challenging area of oncology. He is actively engaged in partnering with researchers and oncologists in academia and pharmaceutical industry worldwide, to advance discovery of biomarkers for early cancer detection and risk assessment, personalized therapy, and novel anti-cancer interventions.